Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430416 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
A Phase 1 study of Uveal Melanoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
- 5
- Study locations
NCT01430416: Completed Phase 1 study of Uveal Melanoma, sponsored by Novartis Pharmaceuticals.
NCT01430416 is a Phase 1 study of Uveal Melanoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 153 participants, roughly in line with the 140-participant average among 29 other Uveal Melanoma trials with a reported enrollment target. The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01430416, a Phase 1 study of Uveal Melanoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study has two parts, dose escalation and dose expansion. For dose escalation, the primary objective is to estimate the maximum tolerated dose (MTD) of AEB071 in patients with uveal melanoma. For dose expansion, the primary objective is to characterize the safety and tolerability of the MTD of AEB071 in patients with uveal melanoma.
Conditions Studied
Interventions
- DRUG AEB071
Study Locations (5)
Other
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Leiden
- Novartis Investigative Site - London
Massachusetts
- Dana Farber Cancer Institute DFCI - Brookline - Boston
New York
- Memorial Sloan Kettering MSKCC 4 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2011-12-20 |
| Est. Completion | 2019-05-22 |
| Phase | Phase 1 |
What the finished NCT01430416 record still lists
NCT01430416 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 140-participant average among 29 other Uveal Melanoma trials with a reported enrollment target.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which AEB071 is the first listed.
NCT01430416 lists 5 locations in 3 states (Other, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT01430416 about?
NCT01430416 is a clinical study titled "Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients". This study has two parts, dose escalation and dose expansion. For dose escalation, the primary objective is to estimate the maximum tolerated dose (MTD) of AEB071 in patients with uveal melanoma. For dose expansion, the primary objective is to characterize the safety and tolerability of the MTD of A...
What is the current status of trial NCT01430416?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2011-12-20. Estimated completion is 2019-05-22.
What conditions does trial NCT01430416 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT01430416?
The interventions under investigation include: AEB071 (DRUG).
Who is sponsoring clinical trial NCT01430416?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01430416 being conducted?
This trial has 5 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01430416's enrollment target sits among peer trials
153 7th of 29 higher than 23 of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
RECRUITING · Phase 1
-
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
ACTIVE NOT RECRUITING · Phase 1
-
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI